Devopharma ApS
CVR 38968254 · Private limited company (ApS) · Active · Low risk
Devopharma ApS is a Private limited company (ApS), founded on , based in Charlottenlund. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.6% over the next 12 months, which is 0.4 times the average for Danish companies. 8 annual reports have been published, of which 6 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 25k and a net result of DKK -3,125. CEO: Henrik Nakskov, Søren Luplau-Pagh.
Bankruptcy risk for Devopharma ApS
0.4 × the average (1.41%) · higher risk than 66% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 38968254
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (9 years)
- Address
- Strandvejen 301, 2.
2920 Charlottenlund - Municipality
- Gentofte
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 50k
- Auditor
- MBA STATSAUTORISERET REVISIONSANPARTSSELSKAB
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 7 of 8 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 25.0% |
| Current ratio | 67% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 2 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 6 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -3,125 | DKK -3,125 |
| Net profit | DKK -3,125 | DKK -3,125 |
| Equity | DKK 25k | DKK 28k |
| Total assets | DKK 100k | DKK 100k |
| Cash | DKK 0 | – |
| Short-term debt | DKK 75k | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · MBA STATSAUTORISERET REVISIONSANPARTSSELSKAB.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 191 | Late | |
| 1 Jan 2024 – 31 Dec 2024 | 187 | Late | |
| 1 Jan 2023 – 31 Dec 2023 | 190 | Late | |
| 1 Jan 2022 – 31 Dec 2022 | 183 | ||
| 1 Jan 2021 – 31 Dec 2021 | 185 | Late | |
| 1 Jan 2020 – 31 Dec 2020 | 194 | Late | |
| 1 Jan 2019 – 31 Dec 2019 | 243 | Late | |
| 25 Sep 2017 – 31 Dec 2018 | 167 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Henrik Nakskov | Current | |
| CEO | Søren Luplau-Pagh | Current | |
| CEO | Morten Olesen | ||
| CEO | Allan Anesteen Tharuman | ||
| Owner (50%) | HN HOLDING 2010 ApS | Current | |
| Owner (25%) | Friendly Holding ApS | Current | |
| Owner (15%) | JARCO HOLDING ApS | Current | |
| Owner (10%) | GAIN ApS | Current | |
| Owner (20%) | Allan Anesteen Tharuman | ||
| Owner (25%) | Stephan Dr Braun | ||
| Auditor | MBA STATSAUTORISERET REVISIONSANPARTSSELSKAB | ||
| Founder | Allan Anesteen Tharuman | Current | |
| Founder | HN HOLDING 2010 ApS | Current | |
| Founder | Friendly Holding ApS | Current |
The CEOs' other companies
Henrik Nakskov – 6 other companies
- 1STWAVE ApS Active
- CABA APS Active
- CIMS 2015 APS Active
- CIMS eSystems A/S Active
- HN HOLDING 2010 ApS Active
- Safe Implant Technology ApS Active
Søren Luplau-Pagh – 17 other companies
- Aeon Group A/S Active
- CABA APS Active
- ELL HOLDING A/S Fusioneret
- Friendly Cloud IVS Opløst
- P-SECURE ApS Active
- Redpill Linpro Connect A/S Active
- Safe Implant Technology ApS Active
- Selskabet af 26.11.2018 A/S Fusioneret
- Selskabet af 29.06.2021 A/S Fusioneret
- VENZO A/S Active
- VENZO Analytics A/S Fusioneret
- VENZO Business Consulting_West A/S Fusioneret
- VENZO Cyber Security A/S Fusioneret
- VENZO OPERATIONS A/S Fusioneret
- VENZO Public & Healthcare A/S Fusioneret
- VENZO Secure A/S Opløst
- VENZO.nxt A/S Fusioneret
Morten Olesen – 6 other companies
- 1STWAVE ApS Active
- CABA APS Active
- CIMS 2015 APS Active
- CIMS eSystems A/S Active
- COMBIX ApS Active
- HN HOLDING 2010 ApS Active
Allan Anesteen Tharuman – 5 other companies, of which 1 bankrupt
- BEWO ApS Bankrupt 1 May 2026
- EVERYTHING ApS Active
- KILTIN A/S Active
- Kartotek Copenhagen Flagship ApS Active
- Tharuman & Warberg ApS Active
Address history (0 moves)
| Strandvejen 301, 2., 2920 Charlottenlund |
Other companies at the same address
- CABA APS Active
- CIMS 2015 APS Active
- HN HOLDING 2010 ApS Active
- PRQ Holding ApS Active
- SVEND LINDBÆK ApS Opløst
- fiveoakgroveholdings ApS Active
Similar companies in Gentofte
- SNL BioSolutions ApS Hellerup
- NIVI Development A/S Hellerup
- Neo Biopharm ApS Hellerup
- G2B BioSolutions ApS Hellerup
- Beatsco2 ApS Charlottenlund
- MHJ Research ApS Hellerup
- XY Therapeutics ApS Charlottenlund
- Lophora ApS Charlottenlund
- CABA APS Charlottenlund
- C- ApS Hellerup
- UNION therapeutics A/S Hellerup
- Aktieselskabet af 1. juni 2011 II Hellerup
Questions and answers about Devopharma ApS
Has Devopharma ApS gone bankrupt?
No, Devopharma ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Devopharma ApS?
Our model estimates a bankruptcy risk of 0.6% over the next 12 months (low risk), which is 0.4 times the average for Danish companies.
Who is the CEO of Devopharma ApS?
Henrik Nakskov, Søren Luplau-Pagh are the CEOs of Devopharma ApS.
Who is the auditor of Devopharma ApS?
Devopharma ApS most recently used MBA STATSAUTORISERET REVISIONSANPARTSSELSKAB.
When was Devopharma ApS founded?
Devopharma ApS was founded on 25 September 2017.
What is the equity of Devopharma ApS?
Equity was DKK 25k according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.